Multiomic Analysis of TIL Suggests That CD4+ Polarization Represses TIL Expansion and CD8+ Activation and is Associated with Progression of Disease. Cien anos de microglia: Milestones in a century of microglial research. Wu, A novel immunostimulatory TLR7/8 agonist is curative as a monotherapy in Lewis Lung Carcinoma and synergizes with anti-PD-1 in B16F10 and MC38 tumor models, Shannon M. Miller, PhD; Caleb Beyer; Danielle Talbot; Konner Jackson; Margaret Whitacre; Janine Ward; Roman Schoener; Helene G. Bazin, PhD; David Burkhart, PhD, Antigen presenting cells;B cell;Checkpoint blockade;Costimulation;Cytokine;Monocyte/Macrophage;Myeloid cells;Solid tumors;TLR;Tumor infiltrating lymphocytes (TILs), Systemic administration of TLR7/8 agonist micelles triggers a potent anti-tumor response mediated by neutrophils as primary effector cells followed by establishment of an immune memory response, Simon S. Jensen, PhD; Esben Christensen, PhD; Morten Just Petersen; Anders Hansen, PhD; Martin Bak, PhD; Camilla Stavnsbjerg, PhD; Svetlana Panina, MD, PhD; Thomas Andersen, PhD, Granulocyte;Solid tumors;TLR;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, EGFR-Ta:RNA: Multimodal mechanism of action potentiates immune checkpoint inhibitor activity, Babette Schade, PhD; Derrick Broka; Caroline De Feyter; Shoshana Klein, PhD; Alexei Shir, PhD; Alexander Levitzki, Prof; Davor Bajic, PhD; Lucia DAmico, PhD; David Colecchia, PhD; Eric Kitas, PhD; Anita Jarzebinska, PhD; Esteban Pombo-Villar, PhD; Maya Zigler, Dr, RNA;Solid tumors;Targeted therapy;TLR;Tumor microenvironment, CAN1012: a Selective and Potent TLR7 Agonist with Strong Antitumoral Properties Mediated by Localized Innate Immune Activation, Henry Yu, PhD; Hong-Ming Hu, PhD; Rongliang Lou, PhD; Wanping Geng, PhD; Sanlong Wang; William L. Redmond, Ph.D.; Yoshinobu Koguchi, MD, PhD; Baotian Qin; John Mao, PhD; Shaoshan Wang, PhD, Antigen presenting cells;Chemokine;Clinical trial;Cytokine;Dendritic cell;Immune adjuvant;MDSC;T cell;TLR;Tumor microenvironment, A unique dendritic cell activation states utilizes inflammasomes to stimulate anti-tumor immunity in mice, Dania Zhivaki; Kelsy Finn, PhD; Emily Gosselin, PhD; Holly Concepcion, BS; Andrew Cornforth, PhD; Caitlin Sullivan, BS, Antigen presenting cells;Cytokine;Dendritic cell;Immune adjuvant;Inflammation;Neoantigens;Solid tumors;T cell lineages;TLR;Vaccine, ST101, a peptide antagonist of novel I/O target CEBP, reprograms MDSC polarization and decreases tumor-associated Tregs, suggesting an immune component to observed clinical responses, Claudio Scuoppo; Gerald S. Falchook, MD, MS; Elisa Fontana; Anja Williams; Nehal J. Lakhani, MD; Jeff Evans; Fabio Iwamoto; Meredith McKean, MD; Stefan N. Symeonides, MD PhD; Alistair McLaren; Jason Henry, M.D. ; Qin Li, PhD; Ashok Gupta; Ikbel Achour, PhD; Brian Fitzgerald; Vamsidhar Velcheti, MD FACP; Anant Madabhushi, Biomarkers;Checkpoint blockade;Solid tumors;Tumor microenvironment, DeepTCRMatch: An effective way of computing T cells antigen specificity, Seungtae Park, BA; Sungsik Kim, Ph.D.; Hee Joon Jeon; Na Ri Yoon; Bo Ryeong Lee; Sung-Min Kim, PhD; Woong-Yang Park, MD, PhD; Hyung Ju Hwang, Antibody;Bioinformatics;Biomarkers;Neoantigens;Proteomics;Systems biology;T cell;T cell lineages;Targeted therapy;Vaccine, Methods to improve co-expression efficacy of genes modulating promoter and linker, Suji Kim; Jong Moo Hong; Kwanghee Kim; Hee Jin Lee; Gyungyub Gong, Adoptive immunotherapy;Gene expression;T cell, Discovery of blood pharmacodynamic biomarkers for ATR inhibitors, Ya Kong; Lulu Jiang; Bin Jiang; Hui Yuwen; Jay Mei; Bo Shan; Bing Hou, Ph.D, Bioinformatics;Biomarkers;Chemokine;Cytokine;Gene expression;RNA;Targeted therapy, An NGS assay to identify HLA loss of heterozygosity for future CEA and MSLN logic-gated CAR-T solid tumor protocols designed for reduced on-target, off-tumor toxicity, Scott Kopetz, PhD; Maria Pia Morelli; Julian R. Molina, MD, PhD; Diane M. Simeone, MD; J. Randolph Hecht, MD; Kedar Kirtane; Mitesh J. Borad, MD; Theodore H. Welling; Edward B. Garon; Armen Mardiros; Xueyin Wang; Eric W. Ng, MD; Tyler Danek; Shannon Gallagher; Ariane Lozac'hmeur; Karl Beutner; John S. Welch; David G. Maloney, MD, PhD; William Y. Breij, PhD, Antibody;Biomarkers;Bispecifics;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor antigens, Selective Small Molecule Inhibitor of Integrin . Vishal Kothari, Ph.D.; Colin Magowan, B.A. Deficiency of metabolic regulator PKM2 activates the pentose phosphate pathway to generate TCF1+ progenitor CD8 T cells to improve efficacy of PD-1 checkpoint blockade. Liang Lin; Vishal Khairnar; Harish Potu; Hao-Ming Chang; Elisabetta Burchi; Armin Rath; Stanley Frankel; Jean Kadouche; Daniel Teper; Wei Li; Antonio Arulanandam, A biparatopic anti-HER2 antibody enabled with conditional 4-1BB agonism induces potent anti-tumor efficacy, Liandi Chen; Weifeng Huang; Xiaoniu Miao; Shaogang Peng; Chao Wang; Yao Yan; Chuan-Chu Chou, PhD; Andy Tsun; Yi Luo, Antibody;Bispecifics;Costimulation;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, Targeting immunosuppressive macrophages and Tregs by repurposing metabolic drugs, Shipeng Chen; Ana Milena Vizcaino; Yuzhen Gao; Baukje Nynke Hoogenboom; Toos Daemen; Cesar Oyarce, Immune suppression;Metabolism;Monocyte/Macrophage;Myeloid cells;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies, Natasha Girgis, PhD; Yu Christie; Zohra Merazga, MSc; Steven Hatfield; Alex Histed; Fan Zhao, PhD; Raymond J. Moniz, PhD; Kristin Yeung; Fulvio Diaz; Wynona Bautista; John F. Ross; Saso Cemerski, PhD; Anish Suri, PhD; Matteo Levisetti; Steven N. Quayle, Inhibition of acid sensing by GPR65 normalises gene expression in macrophages, increases immune cell infiltration in tumors, and restrains subcutaneous MC38 growth in mice, Alastair L. Corbin, DPhil; Stuart Hughes, PhD; Mussa Quareshy, PhD; Tobias Bopp, PhD; Barbara Cipriani, PhD; David J. Miller, PhD; Alan Naylor, PhD; Gavin Milne, PhD; Darryl Turner; Barbara Young, PhD; Anastasia Nika, MSc; Preeti Singh; Rupert Satchell, PhD; Sourav Sarkar, PhD; Gavin Knox, MSc; Toszka Bohn, PhD; Tom McCarthy, PhD, Gene expression;Immune suppression;Monocyte/Macrophage;NK/NKT cell;Solid tumors;Tumor infiltrating lymphocytes (TILs), Preclinical Activity and Safety Profile of JANX007, a Novel PSMA-Targeting Tumor-Activated T Cell Engager for Treatment of Metastatic Castration-Resistant Prostate Cancer, Shahram Salek-Ardakani; Thomas R. DiRaimondo; Natalija Budimir; Simon Shenhav; Hua Wu; Vanessa Cicchini; Renee Jocic; Lina Ma; Fabrece Roup; Calvin Campbell; Carolina Caffaro; Hans Aerni; Ugur Eskiocak; Wayne Godfrey; Charles Winter; Marc Nasoff; Neil Gibson; David Campbell, A Bifunctional Tumor Activated Immunomodulator (TRACIr) Targeting PD-L1 And CD28 Is a Potent Enhancer of T Cell-Mediated Anti-Tumor Activity, Shahram Salek-Ardakani; Thomas R. DiRaimondo; Natalija Budimir; Lina Ma; Simon Shenhav; Vanessa Cicchini; Robert Navert; Hua Wu; Renee Jocic; Cuiling Yu; Diane Aceveda; Hannah Best; Clara Prentiss; Kai Muskat; Jason Chang; Farhad Dastmalchi; Fabrece Roup; Carolina Caffaro; Hans Aerni; Wayne Godfrey; Charles Winter; Marc Nasoff; Neil Gibson; David Campbell; Shahram Salek-Ardakan, Antibody;Bispecifics;Checkpoint blockade;Coinhibition;Costimulation;Solid tumors;T cell;Tumor microenvironment, Novel GCN2 modulator HC-7366 decreases pulmonary metastases and reduces myeloid-derived suppressor cells, Jeremy Drees, PhD; Anissa S.H. This session will feature recent work in the field examining pathways and molecules that cause neurological dysfunction, with a particular emphasis on genetic neurodevelopmental disorders. Microglial MorphOMICs unravel region- and sex-dependent morphological phenotypes from postnatal development to degeneration. Alexa R. Heaton, PhD; Anna Hoefges, MS; Peter R. Rehani, BS; Nathaniel J. Burkard; Arika S. Feils, BS; Dan V. Spiegelman, BS; Noah W. Tsarovsky, BS; Alina Hampton; Amy K. Erbe, PhD; Alexander L. Rakhmilevich, MD, PhD; Paul M. Sondel, MD, PhD; Melissa C. Skala, Ph.D. Antibody;Checkpoint blockade;Immune contexture;Metabolism;Radiotherapy;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Vaccine, Delta-radiomics predicts response and overall survival in advanced non-small cell lung cancer patients treated with durvalumab, Mohammadhadi Khorrami, PhD; Vidya Sankar Viswanathan, M.B.B.S. Willumsen, PhD; David McDermott, MD; Toni K. Choueiri, MD, Biomarkers;Checkpoint blockade;Clinical trial;Solid tumors. Distinct types of microglial activation in white and grey matter of rat lumbosacral cord after mid-thoracic spinal transection. ; Ian F. Pollack, M.D. Biomarkers;Checkpoint blockade;Clinical study;Clinical trial;Immune monitoring;Solid tumors;T cell. Banks, MD PhD; Smita S. Chandran, PhD; Arianna Correa; Bryan C. Novak; Jessica M. Fleischman; Alexander Drilon, MD; Jedd D. Wolchok, MD PhD; Taha Merghoub, PhD; Christopher A. Klebanoff, MD, Adoptive immunotherapy;Immune monitoring;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs), The Functional Activity of Gavo-cel TRuC-T Cells is not Impaired by Soluble Mesothelin, Michael Lofgren, PhD; Robert Tighe, PhD; Robert Hofmeister, PhD; Jian Ding, PhD; Nate Bagge, BS; Alec Andrews, MS; Michelle Fleury, PhD; Courtney Anderson, PhD, Clinical trial;Solid tumors;T cell;Tumor antigens;Tumor evasion;Tumor microenvironment, Luciferase reporter cancer cell lines facilitate CAR-T development, John G. Foulke, MS; Luping Chen, BS; Brian Della Fera, BS; Hyeyoun Chang, PhD; Kevin Tyo, PhD; Zhizhan Gu, MD, PhD; Fang Tian, PhD, Adoptive immunotherapy;Antigen presenting cells;CAR T cells;Immune monitoring;Leukemia/Lymphoma;Solid tumors;Targeted therapy;Tumor antigens, SENTI-401, an Allogeneic Logic-Gated and Multi-Armed CAR-NK Cell Therapy for the Treatment of CEA-Expressing Solid Tumors with Enhanced Selectivity and Efficacy, Alba Gonzalez Junca, PhD; Nicholas Frankel, PhD; Maelig Morvan, PhD; Assen Roguev, PhD; Michelle Hung, PhD; Russell Gordley, PhD; Miguel R. Palermo; Tyler Santomaso; Pearley Chinta; Aldo Sotelo, MS; Marcus Gainer, MS; Derrick Lee; Tony Hua, PhD; Andrew Banicki; Mengxi Tian; Niran Almudhfar; Atahualpa Contreras; Chen-Ting Lee, PhD; Timothy K. Lu, PhD, Adoptive immunotherapy;Cytokine;NK/NKT cell;Solid tumors;Tumor antigens;Tumor microenvironment, Developing an Adoptive Cell Transfer Immunotherapy for Pediatric High-Grade Gliomas. The overarching goal is to organize an exciting and interactive interest group session, expand the array of participants and trigger new synergy among researchers in the mitochondria and age-associated disease fields. De novo transcript sequence reconstruction from RNA-seq using the Trinity platform for reference generation and analysis. The glycocalyx in tumor progression and metastasis, The heparaase/syndecan-1 axis in cancer progression, Reprogramming T cells to target glycans and overcome glycan-mediated immunosuppression for cancer therapy, Orchestrated intragranular restructuring of mucins during secretory granule maturation, Phase behavior of intrinsically disordered prion-like domains, Liquid-liquid phase separation modulated by post-translational modifications and its implications for gene regulation, Polyubiquitin effects on phase transitions of shuttle protein UBQLN2, Visualizing the dynamic genome during development, Engineering the repetitive 3D genome in human disease. We developed a research-based master's program in biochemistry from an NSF S-STEM training grant to fund low-income students and increase diversity of associated departments. Quantification of the rat spinal microglial response to peripheral nerve injury as revealed by immunohistochemical image analysis and flow cytometry. de Beijer, MSc; Michael Doukas, MD, PhD; Jeroen A.A. Demmers, PhD; Anna-Sophia Wiekmeijer, PhD; Willem-Jan Krebber, MSc; Cornelis J. Melief, MD, PhD; Jan N. IJzermans, MD, PhD; Jaap Kwekkeboom; Sjoerd H. van der Burg, Prof.Dr. Histogenesis and normal evolution: exodus and regional distribution of microglia. ; Grace Antony; Eleftherios Zografos; Jennifer Veneris; Ana Oaknin, MD, Checkpoint blockade;Clinical study;Solid tumors, A Phase 1 adoptive cell therapy using drug-enhanced, tumor-infiltrating lymphocytes, DeTIL-0255, in adults with advanced malignancies, Eugenia Girda, MD; Emese Zsiros, MD, PhD; John Nakayama, MD; Sarah Whelan, PhD; Srinand Nandakumar; Seema Rogers; Beverly Benson; Michael T. Lotze, MD; Robert J. Ramified microglia were traditionally associated with the resting state, although we now know that ramified microglia actively play many functions during normal physiological conditions. ; Jessica L. Christenson, Ph.D.; Nicole S. Spoelstra, B.S. Aideen E. Ryan, PhD; Oliver Treacy, PhD; Kevin Lynch, PhD; Kim De Veirman; Karin Vanderkerken; Laurence J. Egan, Prof; Thomas Ritter, Prof; Aisling M. Hogan; Keara Redmond; Sean Hynes; Emma M. Kerr, PhD; Michael O'Dwyer; Philip D. Dunne; Niamh A. Leonard, MSc; Hannah Egan, BSc, Checkpoint blockade;Glycoproteomics;Immune suppression;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma, AIM2 modulates azacytidine-induced antitumor immunity in lung cancer, Naoki Furuya, MD, PhD; Sumei Lu, PhD; Tamio Okimoto, MD, PhD; Yi Wang; No Joon Song; Anqi Li, MD; Hong Dong, PhD; Bao Zhao; Ju Hwan Cho, PhD; David P. Carbone, MD, PhD; Zihai Li, MD, PhD; Haitao Wen; Kai He, MD, PhD, Biomarkers;Epigenetics;Inflammation;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, Multiplexed ion beam imaging identifies B-cell enrichment in the RHAMM-high invasive niche of breast cancer, Yuyu He, MD, MS; Grant M. Barthel; Raghav Padmanabhan; Colleen Forster; Hanna Root; Mate L. Nagy, PhD; Stanislaw Nowak, PhD; James B. McCarthy; Kathryn L. Schwertfeger; Andrew C. Nelson, B cell;Biomarkers;Monocyte/Macrophage;T cell;Tumor microenvironment;Tumor stroma. These are questions authors ask themselves when preparing manuscripts for publication. Function and Dysfunction of Microglia during Brain Development: Consequences for Synapses and Neural Circuits. ; Chris La Placa, M.S. Immunofluorescence Staining Using IBA1 and TMEM119 for Microglial Density, Morphology and Peripheral Myeloid Cell Infiltration Analysis in Mouse Brain. PARP inhibition increases in the suppressive capacity of tumor-associated Tregs in a BRCA1-deficient model of ovarian cancer. Bold, MD; Sean J. ; Doron Merkler; Andrew Janowczyk; Diego G. Dupouy, PhD; Aitana Neves; Thomas McKee, Proteomics;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, From TCR-pMHC binding kinetic characteristics to TCR phosphorylation and initiation of signal transduction, Jonathan Desponds; Mayra Cruz Tleugabulova; Jeanne Cheung; Shirley Ng Palace; Martine Darwish; Geraldine Strasser; Andrey Shaw; Ira Mellman, PhD; Andrei Chernyshev; Darya Orlova, PhD, Adoptive immunotherapy;Bioinformatics;Neoantigens;Solid tumors;Systems biology;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs), Identification of clinically relevant spatial tissue phenotypes in large-scale multiplex immunofluorescence data via unsupervised graph learning in non-small cell lung cancer, Robert Egger; Andrew Fisher; Michael G. Drage; Jimena Trillo-Tinoco, PhD; John Abel; Andrew Browne; Deepta Rajan; Tai Wang; Jake Conway; Catherine King; Jacqueline Brosnan-Cashman, Ph.D.; Anne Lewin; Arnaud Amzallag; Thomas Lila; Tyler Simpson; Mike Montalto; Benjamin Chen, MD,PhD; Benjamin Glass, MS; Vipul Baxi, MS, Biomarkers;Gene expression;Tumor microenvironment;Tumor stroma, Crossdome: An interactive R package to predict T-cell cross-reactivity risk on immunopeptidomics databases, Andre F. Fonseca, PhD; Dinler A. Antunes, PhD, Adoptive immunotherapy;Bioinformatics;Gene expression;Tumor antigens, A novel graphical deep neural network learning approach utilizing molecular data for optimizing patient selection for treatment with immune checkpoint inhibitors: An ORIEN pan-cancer study, Issam M. El Naqa, Ph.D.; Payman Ghasemi, PhD; Aik Choon Tan, PhD; James Chen; Aakrosh Ratan; Martin McCarter, MD; John D. Carpten, PhD; Howard Colman, MD; Alexandra Ikeguchi, MD; Igor Puzanov, MD, MSCI, FACP; Susanne M. Arnold, MD; Michelle L. Churchman, PhD; Patrick Hwu; Jose Conejo-Garcia, MD, PhD; William (Bill) S. Dalton, PhD, MD; George J. Weiner, MD; Ahmad A. Tarhini, MD, PhD, MS, Biomarkers;Checkpoint blockade;Gene expression;Immunoscore;Tumor microenvironment, Radiomic and clinical prediction of overall and organ-specific response to ipilimumab-nivolumab in melanoma, Zane N. Gray, MS; Alexandra Tompkins; Rebekah Dadey, PhD; Serafettin Zenkin; Afsaneh Amouzegar, MD; Priyadarshini Mamindla; Vishal Peddagangireddy; Murat Ak; Ryan C. Augustin, MD; Rivka Colen; Riyue Bao, PhD; Jason J. Luke, MD, Recurrence prediction in cutaneous melanoma patients by exploiting deep learning on H&E slide images, Michele Guida, MD; Maria Colomba Comes; Livia Fucci; Sabino Strippoli; Samantha Bove; Ivana De Risi; Annarita Fanizzi; Martina Milella; Fabio Mele; Alfredo Zito; Raffaella Massafra, Bioinformatics;Biomarkers;Immune adjuvant, Concordance analysis of AI-powered CD8 quantification and automated CD8 topology with manual histopathological assessment across seven solid tumor types, Maria Guramare; Nishant Agrawal; George Lee, PhD; Adam Stanford-Moore, MS; Abhik Lahiri; Diksha Meghwal; Aryan Pedawi; Darren Fahy; Raymond Biju; Archit Khosla; Dimple Pandya, MD; Scott Ely, MD, MPH; Jimena Trillo-Tinoco, PhD; John B. Wojcik, MD, PhD; Falon D. Gray, DVM; Benjamin Chen, MD,PhD; Sergine Brutus; Benjamin Glass, MS; Cyrus Hedvat, MD, PhD; Ilan Wapinski; Michael Montalto; Andrew H. Beck; Charles Biddle-Snead; Vipul Baxi, MS, Biomarkers;Immune contexture;T cell;Tumor infiltrating lymphocytes (TILs), Applying machine vision to empower preclinical development of immunotherapies in patient-derived organoid models of solid tumors, Chi-Sing Ho, PhD; Sonal Khare, PhD; Madhavi Kannan, MS; Michael Streit, MS; Timothy D. Lopez, MS; Luca Lonini, PhD; Brian Larsen, PhD; Brandon L. Mapes, MS; Jenna Shaxted, BS; Martin C. Stumpe, PhD; Ameen A. Salahudeen, PhD; Jagadish Venkataraman, PhD, Adoptive immunotherapy;Bispecifics;CAR T cells;Tumor infiltrating lymphocytes (TILs), Biology-guided Deep Learning Predicts Prognosis and Cancer Immunotherapy Response, Yuming Jiang, MD, PhD; Zhicheng Zhang, PhD; Wei Wang, MD; Weicai Huang; Chuanli Chen, MD; Sujuan Xi, MD, PhD; M. Usman Ahmad, MD; Yulan Ren, BS; Shengtian Sang, PhD; Jingjing Xie, PhD; Wenjun Xiong, MD, PhD; Tuanjue Li, MD, PhD; Zhen Han, MD, PhD; Qingyu Yuan, MD; Yikai Xu, MD; Lei Xing, PhD; George A. Poultsides, MD; Guoxin Lin, MD, PhD; Ruijiang Li, Checkpoint blockade;Chemotherapy;Immune monitoring;Immunoscore;Solid tumors;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma, Spatial analysis of tumor-infiltrating lymphocytes (TILs) based on HER2 expression across multiple cancer types, Sukjun Kim, PhD; Seulki Kim; Yoojoo Lim; Gahee Park; Sanghoon Song; Heon Song; Seonwook Park; Jeongun Ryu; Sergio Pereira; Donggeun Yoo; Kyunghyun Paeng; Chan-Young Ock, MD, PhD, Biomarkers;Gene expression;Systems biology;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, Structure-based prediction of neoantigens paired with T cell receptors on phenotype-selected CD8+ tumor-infiltrating lymphocytes, Bo Ryeong Lee, PhD; Sungsik Kim, Ph.D.; Sung-Min Kim, PhD; Woong-Yang Park, MD, PhD, COVID and Immunotherapy;Gene expression;Neoantigens;Solid tumors;T cell;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Vaccine, Radiomics and delta-radiomics signatures to predict response and survival in patient with non-small cell lung cancer treated with immune checkpoint inhibitors, Franois Cousin; Thomas Louis; Mariaelena Occhipinti; Wim Vos; Julien Guiot; Roland Hustinx, Antibody;Bioinformatics;Biomarkers;Solid tumors, Spatial transcriptomics-enabled integrated morphology-transcriptome tumor cell phenotyping using machine learning, Nga H. Luong; Wei Yan; Jeffrey C. Lim; Yuezhen Xue; Abu Bakr Azam, M.Engg; Joe Poh Sheng P. Yeong, MD, PhD; Mai Chan Lau; Yiyu Cai, PhD, Bioinformatics;Gene expression;RNA;Solid tumors;Tumor stroma, Predicting response to immune checkpoint inhibitors (ICI) in non-small-cell lung cancer (NSCLC) by combining spatial analysis of cells and RNA sequencing data from biopsies using deep learning (DL), Ettai Markovits, MD; David Soong, PhD; Becky Arbiv; Alon Groisman; Maya Lipinsky; Yoni Yedidia; Yoad Cohen; Yuval Gabay; Yuval Shachaf; Eyal Oren; Roman Gluskin; Ido Weiss; Hisham Hamadeh; Kate Sasser; Gali Golan; Brandon Higgs; Suzana Couto; Ori Zelichov, MD, Biomarkers;Checkpoint blockade;Immune contexture;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, A deep learning analysis pipeline for multiplex imaging identifies spatial features associated with clinical outcome in colorectal cancer, Ettai Markovits, MD; Roman Gluskin; Tomer Dicker; Ido Weiss; Sun Dagan; Ron Elran; Amit Bart; Oleg Kuybeda; Becky Arbiv; Ori Zelichov, MD, Bioinformatics;Biomarkers;Immune contexture;Solid tumors;T cell;Tumor microenvironment;Tumor stroma, A multi-tumor machine learning model to identify tertiary lymphoid structures in histopathological H&E images as a potential clinical biomarker, Vanessa Matos-Cruz, Ph.D.; Rachel L. Sargent, MD; Varsha Chinnaobireddy; Maryam Pouryahya; George Lee, PhD; Darren Fahy; Christian Kirkup; Kathleen Sucipto; Sai Gullapally; Jacqueline Brosnan-Cashman, Ph.D.; Archit Khosla; Nishant Agrawal; Benjamin Glass, MS; Sergine Brutus; Limin Yu; Benjamin Chen, MD,PhD; Vipul Baxi, MS; Scott Ely, MD, MPH, B cell;Biomarkers;Inflammation;Solid tumors;T cell;Tumor microenvironment, A reproducible pipeline for analysis of multiplex imaging (MIBI) data with application to uncovering novel features of the tumor-immune microenvironment, Jessica Maxey, PhD; Marshall A. Thompson, PhD; Katie Campbell, PhD; Benjamin Kamphaus; Zaid Bustami, BS Candidate; Sandra Santulli-Marotto, PhD; Daniel Wells, BA, PhD; Silvia Boffo, PhD; Lisa M. Salvador; Philip O. Scumpia, MD; Christine N. Spencer, PhD; Adam Schoenfeld; Antoni Ribas, MD, PhD; Lacey J. Kitch, PhD, Bioinformatics;Biomarkers;Systems biology;Tumor microenvironment, Establishing the preclinical PKPD relationship for NM32-2668 a ROR1 targeting T cell engager, Hitesh Mistry, PhD; Fernando G. Ortega; Bithi Chatterjee, PhD; Nicole Bassler; Niels Kirk; Julia Tietz; Belinda Wickihalder; Simone Muntwiler; Simon Carnal; Daniel Snell, PhD; Christopher D. Chassagnole, PhD, Bispecifics;Costimulation;Cytokine;Immune toxicity;Solid tumors;T cell;Targeted therapy;Tumor antigens;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, An Automated Machine Learning Framework for Rapid Quantification and Analysis of Multiplexed Ion Beam Images (MIBI), Raghav Padmanabhan, PhD; Mate L. Nagy, PhD; Stanislaw Nowak, PhD; Peng Si, PhD; Sweta Bajaj, M.S. ; Luc Girard, PhD; Esra Akbay, PhD, Antibody;Checkpoint blockade;Immune monitoring;Immune suppression;NK/NKT cell;Solid tumors;T cell;Tumor antigens;Tumor evasion, The novel telomerase-directed telomere-targeted anticancer agent 6-thio-dG (THIO) demonstrates potent activity and induces antitumor immunity in hepatocellular carcinoma (HCC) models. This work was supported by grants from the Dementia Research Switzerland Synapsis Foundation , Swiss National Science Foundation ( SNSF 310030_197940 ), and European Research Council ( ERC StGrant REMIND 804949 ) to R.C.P. ; Leon Yim, B.S. The origin and identity of microglia was, for many years, a matter of debate. A phase I study of intralymphatic (IL) administration of ipilimumab (IPI) with intravenous nivolumab (NIVO) using the Sofusa DoseConnect™ device in patients with advanced melanoma. The workshop will bring together laboratories using cryo-EM, X-ray crystallography, biochemistry, nuclear microinjection, genetics, cell biology, CRISPR/Cas9-AID gene editing, live imaging, viral and animal models to elucidate interactions between nucleoporins, mRNA and RNA-accessory proteins at the nuclear pore complex. Once abstract titles are listed on the website, press releases can be issued with the titles and logistical information. How to determine whether and when two or more molecules bind to each other in vivo. ; Roman Kischel, PhD; Veit Bcklein, Dr. Chelsey Spriggs, co-founder of Black in Microbiology (#BlackInMicro) and a member of the first cohort of the ASBMB MOSAIC program, will share her journey as a role model for underrepresented students interested in biological research. ; Sean Rowell, BS; Sarah Nikiforow; Gerry MacDonald; Jerome Ritz; Nikhil Munshi; Kenneth Anderson, Cancer vaccine triple synergistic combination immunotherapy enhances anti-cancer efficacy. Daniel Alonso-Miguel, DVM; Guillermo Valdivia, DVM; Barbara Zimmermann, DVM; Lucia Lucia Barreno; Angela Alonso-Diez, DVM; Maria Dolores Perez-Alenza, DVM; Veronique Beiss; Mara Surez-Redondo; Nicole Steinmetz, BS, PhD; Steven Fiering, BS, MS, PhD; Johannes Vom Berg; Laura Laura Pea, DVM; Hugo Arias-Pulido, PhD, Chemokine;Cytokine;Immune adjuvant;Immune monitoring;Tumor microenvironment;Vaccine, Tigilanol tiglate is a naturally occurring small molecule oncolytic that effectively ablates tumors via intratumoural injection and can enhance response to immune checkpoint blockade, Jason K. Cullen, DPhil; Pei-Yi Yap; Blake Ferguson; Zara C. Bruce; Motoko Koyama; Herlina Handoko; Jacinta L. Simmons; Jenny Johns; Marjorie DSouza; Natasa Broit; Praphaporn Stewart; Daniel Shelley; Tracey McMahon; Steven M. Ogbourne, Associate Professor; Yi Chieh Lim, PhD; Giovanni Appendino; Victoria A. Gordon, PhD; Paul W. Reddell, PhD; Glen M. Boyle, Professor; Peter G. Parsons, Professor, Checkpoint blockade;Immune adjuvant;Solid tumors;Tumor infiltrating lymphocytes (TILs), Radiotherapy-activated NBTXR3 nanoparticles induce Interferon Beta secretion by cancer cells, Cytokine;Radiotherapy;Tumor microenvironment, Preclinical Activity and Safety Profile or JANX008, a Novel EGFR-Targeting Tumor-Activated T Cell Engager for Treatment of Solid Tumors, Shahram Salek-Ardakani; Thomas R. DiRaimondo; Natalija Budimir; Lina Ma; Simon Shenhav; Vanessa Cicchini; Hua Wu; Renee Jocic; Fabrece Roup; Calvin Cambell; Carolina Caffaro; Hans Aerni; Ugur Eskiocak; Wayne Godfrey; Charles Winter; Marc Nasoff; Neil Gibson; David Campbell, Intratumoral administration of VAX014 cooperates with checkpoint blockade to reprogram tumor immune microenvironments and clear injected and noninjected tumors, Matthew Giacalone, PhD, MBA; Katherine Reil; Shingo Tsuji; Kinsey Nelson; Elsa Molina; Kathleen McGuire, Checkpoint blockade;Dendritic cell;Immune adjuvant;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma, Intratumoral administration of SARS-CoV-2 reduces tumor progression and alters the tumor immune microenvironment similar to that of the seasonal influenza vaccine, Eileena F. Giurini, MS; Kajal H. Gupta, PhD, Cytokine;Immune adjuvant;Immune monitoring;Solid tumors;T cell;Tumor microenvironment;Vaccine, Molecular mechanisms of DC activation by melanoma cells responding to LTX-315. OxPhos inhibition offsets the metabolic advantage of pancreatic cancer and promotes a pro-inflammatory tumor microenvironment. ; Vivek Mittal, Ph.D. Adoptive immunotherapy;Checkpoint blockade;Gene expression;Metabolism;Solid tumors;T cell;T cell lineages;Tumor infiltrating lymphocytes (TILs), Multispectral Immunohistochemistry reveals an immunosuppressive tumour microenvironment in Esophageal Adenocarcinoma, Charles J. Rayner, MB BS MRCS; Tyler F. Wooldridge, BSc (Hons); Sunny Sunshine; Izhar Bagwan, MBBS, MD, FRCPath; Shaun R. Preston, MD FRCS; Hardev S. Pandha, PhD, FRCP, FRACP, FR; Nima Abbassi-Ghadi, PhD FRCS; Nicola E. Annels, BSc, PhD, Checkpoint blockade;Regulatory T cell (Treg cell);Solid tumors;Surgery;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, Unfavorable neoantigen architectures blunt anti-tumor T cell responses in a mouse model of lung adenocarcinoma, Malte Roerden, MD, PhD; Kim B. Nguyen, B.A. ; Kenny Kwok-Hei Yu, MBBS, Ph.D.; Ruby M. Freeman, B.S. It is also unknown whether changes in states during diseases are inflammatory or dedicated to maintaining microglial homeostatic functions. ; Marina Gonzalez; Peter Wengenmayer; Igor Samoylenko, MD. Loss of IBA1-Expression in brains from individuals with obesity and hepatic dysfunction. (Vocabulary list) Read More Song, MD; Keshu Zhou; Chuan Jin; Zhengzi Qian; Ming Hou; Lei Fan; Fei Li; Kaiyang Ding; Hui Zhou; Xiaoling Li; Bing Chen; Xiuhua Sun; Xianmin Song; Ming Jiang; Qingyuan Zhang; Lihong Liu; Guohua Yu; Yu Hu; Zheng Zhao; Ligen Liu; Hongwei Xue; Jun Luo; Bai He; Zhifang Yao; Fenghua Xu; Min Zhao; Baiyong Li, Ph.D; Yu Xia; Jun Zhu, Antibody;Checkpoint blockade;Clinical trial, Gut microbiota tuning promotes tumor-associated antigen cross-presentation and enhances CAR T antitumor effects, Andrea Facciabene, PhD; Mireia Uribe-Herranz, PhD; Silvia Beghi, PhD; Marco Ruella, MD; Kalpana Parvathaneni, PhD; Guido Ghilrardi, MD; Yung Gu Lee, MD; Noelle Frey; John Scholler; Khatuna Gabunia, Research Specialist; Gary Wu; Elise Chong, MD; David L. Porter, MD; Carl June; Stephen J. Schuster, MD; Vijay Bhoj, MD, Adoptive immunotherapy;Antigen presenting cells;CAR T cells;Microbiome;Tumor antigens, Blood-based extracellular matrix biomarkers are correlated with prognostic and fibrotic-related clinical characteristics and liver function markers in patients with advanced hepatocellular carcinoma, Jaclyn Neely, PhD; Jin Yao, PhD; Christina Jensen; Morten Karsdal, PhD; Nicholas N.W. Byoung S. Kwon, PhD; Hye Jeong KIM; Joong Won Lee, Antibody;Checkpoint blockade;Monocyte/Macrophage;Tumor microenvironment, YH38560, a novel bispecific fusion protein targeting 5T4 and CD47 in a tumor-selective manner for the treatment of solid cancers, Narae Lee, MS; Eunjeong Jeong; Jung-Hoon Pyun; Minji Choi; Young Bong Park; Yoon ha Hwang; Eunjung Lee; Junhwan Kim; Se-Woong Oh, Bispecifics;Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;NK/NKT cell;Solid tumors;Tumor antigens;Tumor microenvironment, Application of Organoid-based Discovery Platform for Innovative Screening, Evaluation, and Identification (ODISEI) in Immunotherapy, Bo Eun Lee, MS; Sarang Kim; Yuri Shin; Hee-Ra Lee; Suyoung Jo; Dong Wook Han; Jongman Yoo, B cell;Bispecifics;Checkpoint blockade;Dendritic cell;Monocyte/Macrophage;Myeloid cells;Regulatory T cell (Treg cell);Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs), Preclinical studies support clinical development of AZD2936, a monovalent bispecific humanized antibody targeting PD-1 and TIGIT, Karin Lee, PhD; Deepali Malhotra, PhD; Stacy Pryts; Eleanor Clancy-Thompson, PhD; Bilal Omar, PhD; Brian Naiman; Michael Overstreet, PhD; Devon K. Taylor; Chunning Yang; Kathy A. Mulgrew; Zhan Xiao; Yue Wang, PhD; Gordon Moody; Mark Cobbold, MD, PhD; Yariv Mazor; Scott A. Hammond, PhD; Kristen N. Pollizzi, PhD, Antibody;Bispecifics;Checkpoint blockade;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs), Botensilimab, an Fc-enhanced CTLA-4 antibody, enhances innate and adaptive immune activation to promote superior anti-tumor immunity in cold and I-O refractory tumors, Chloe Delepine, MEng, MS; Daniel L. Levey, PhD; Shanmugarajan Krishnan, PhD; Kwang-Soo Kim, PhD; Adam Sonabend; Margaret Wilkens; Antoine Tanne, PhD; Pilar Garcia-Brocano; Claire H. Galand, PhD; Haiyong Han, PhD; Christopher MacDermaid; Jacky Chow, PhD, MS; Sylvia Vincent; Shalu Karkwal; Yan Sun; Racehl Smith; Xavier Michelet, PhD; Kah Teong; Katherine Rosenthal, RN, MSN, OCN, CCRP; David Savitsky, PhD; Cailin Joyce, PhD; Steven J. O'Day, MD; Joseph E. Grossman, MD; Jaymin M. Patel, MD; Dhan Chand, PhD, Antibody;Antigen presenting cells;Checkpoint blockade;Clinical study;Costimulation;Dendritic cell;Gene expression;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs), Transient inhibition of cyclin-dependent kinase 4/6 with trilaciclib enhances inhibitory receptor immunotherapy to improve antitumor efficacy, Kun-Hui Lu; Catherine Dietrich; Sarah Ahn; Subing Cao; John S. Yi, PhD; Shom Goel, Checkpoint blockade;Solid tumors;T cell;Tumor microenvironment, Knockdown of VISTA protein using antisense oligonucleotides promotes superior anti-tumor immunity compared to antibody blockade, Brittany A. Morrow, BS; Michael A. Curran, PhD; Priyamvada Jayaprakash, PhD; Alexey Revenko; Patrick Younan, Checkpoint blockade;Granulocyte;Immune suppression;Immune toxicity;MDSC;Monocyte/Macrophage;Myeloid cells;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, PD-1 blockade administered before or at the time of T cell activation enhances anti-tumor immunity, Jena E. Moseman, BSE; Douglas G. McNeel, MD, PhD, Checkpoint blockade;T cell;Tumor infiltrating lymphocytes (TILs);Vaccine, First-in-class anti-PVR mAb NTX1088 restores expression of DNAM1 and augments antitumor immunity, Akram Obeidat, PhD; Anas Atieh; Alon Vitenshtein; Guy Cinamon, PhD; Keren Paz, PhD; Tihana Rovi; Paola Brilc; Lea Hirsl; Ofer Mandelboim; Stipan Jonjic; Pini Tsukerman, PhD, Antibody;Biomarkers;Checkpoint blockade;Clinical trial;Immune suppression;Myeloid cells;NK/NKT cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs), Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockade, Namrata S. Patil, Ph.D.; Raymond Meng, PhD; Robert Johnston; Patrick S. Chang; Shyam Srivats; Yoonha Choi; Xiangnan Guan; Barzin Y. Nabet, PhD; Lisa McGinnis; Eugene Chiang; Thinh Pham; Alexis Dunkle; Bill OGorman; Ira Mellman, PhD; Ruozhen Hu; John Silva; Joy Han; Amelia Au-Yeung; Chikara Takahashi; Nandini Molden; Pallavi Daggumati; Wendy Connolly; Melissa L. Johnson, MD; Delvys Rodriguez Abreu; Byoung Chul Cho, MD, PhD; Antoine Italiano, MD, PhD; Ignacio Gil Bazo; Enriqueta Felip; Sanjeev Mariathasan, PhD; Carlos Bais; David S. Shames, PhD, Checkpoint blockade;Myeloid cells;Regulatory T cell (Treg cell);T cell, LAIR-1 inhibition enhances anti-PD-1 efficacy, Yoshiko Takeuchi, MD PhD; Corazon D. Arthur; Heather N. Kohlmiller; James M. White; Betty Lee; Bin Fan; Jiawei Huang; James Sissons; Jonathan Sitrin; Lee Rivera; Robert D. Schreiber, PhD, Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;Neoantigens;Solid tumors, HBM1047, a novel fully human anti-CD200R1 antagonist antibody with potent anti-tumor efficacy in preclinical model, Yuhua Wang, Ph.D; Qiumei Du; Hongjie Pan; Geetika Bajpai; Tao Liu; Jason Noon; Yao Lu; Jinqiu He; Yan Li; Qingfang Chen; Yongqiang Wang; Xingxing Jia; Fei Chen; Youhong Wang; Yiping Rong; Yun He; Joe Zhao; Musheng Bao, Antibody;Antigen presenting cells;Checkpoint blockade;Coinhibition;Immune suppression;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs), Real-world outcomes in patients with penile squamous cell carcinoma (pSCC) receiving immune checkpoint inhibitors (ICI), Tony Z. Zhuang, MD; Subir Goyal, MBBS, PhD, MSc; Jacqueline T. Brown, MD; Bradley C. Carthon, MD, PhD; Omer Kucuk, MD; Greta R. McClintock, MSN, FNP, DC; Lauren Yantorni, ARNP; Mehmet A. Bilen, MD; Viraj A. Dictys: dynamic gene regulatory network dissects developmental continuum with single-cell multi-omics, Single-cell normalization and association testing unifying CRISPR screen and gene co-expression analyses with Normalisr, SCENIC: single-cell regulatory network inference and clustering, Inferring gene regulatory networks from time-stamped single cell transcriptional expression profiles, A Scanpy extension for analyzing single-cell T-cell receptor (TCR) sequencing data, Multiset multicover methods for discriminative marker selection, SCMarker: ab initio marker selection for single cell transcriptome profiling. ; Megan M. Wyatt, MS; Chrystal M. Paulos, PhD; Jessica E. Thaxton, PhD, MS; Shikhar Mehrotra, PhD; Haydn Kissick, PhD; Mark P. Rubinstein, PhD; Gregory B. Lesinski, Ph.D. Adoptive immunotherapy;Metabolism;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs), Neutralizing oxidative damage at telomeres prevents T cell dysfunction and improves adoptive cell therapy, Dayana B. Rivadeneira, PhD; Sanjana Thosar; Konstantinos Lontos, MD, PhD; Jessica A. Jana, BSE; Marcel Bruchez; Patricia L. Opresko; Greg M. Delgoffe, PhD, Manufacturing of a clinical scale CD8 TIL product, AGX148, with and without gene silencing of PD-1 using self-delivering RNAi INTASYLTM PH-762, Colin J. Thalhofer, PhD; Simon P. Fricker, PhD; Ryan D. Montler, MBA; Elaine A. Ballinger, PhD; Nick P. Morris, PhD; Jake Moses, BS; Dingxue Yan; Tarsem L. Moudgil, MS; Bernard A. - Gene Expression Quantification (Coverage,FPKM) Microbiota-derived acetate enables the metabolic fitness of the brain innate immune system during health and disease. Linnaeus and the Linnaeans: The Spreading of their Ideas in Systematic Botany, 1735-1789. ; Erin H. Budi, Ph.D.; Prerna Kotak, M.A. ; Saska Brajkovic, PhD; Diego G. Dupouy, PhD, Antibody;Biomarkers;Checkpoint blockade;Immune contexture;Proteomics;Solid tumors;T cell;Tumor microenvironment;Tumor stroma, Fully automated spatial multi-omics analysis to map the tumor microenvironment with single-cell resolution, Pino Bordignon, PhD; Alice Comberlato, PhD; Saska Brajkovic, PhD; Diego G. Dupouy, PhD, Antibody;Biomarkers;Cytokine;Gene expression;Proteomics;RNA;Solid tumors;T cell;Tumor microenvironment;Tumor stroma, Interrogating Elite Responder humoral responses to identify novel targets and therapeutic antibodies for the treatment of cancer, Ramya Chandrasekaran, M.S. Are you sure you want to create this branch? and Genetics, Washington University, St. Louis), Alicia Oshlack (Murdoch Children's Research Institute, Australia), Dana Pe'er (Memorial Sloan Kettering Cancer Center, USA), Charlotte Soneson (Institute of Molecular Life Sciences, University of Zurich), Sarah Teichmann (Wellcome Trust Sanger Institute, UK), Barbara Treutlein (Max Planck Institute for Evolutionary Anthropology, Germany), Catalina Vallejos (The Alan Turing Institute & UCL, UK), Stein Aerts (KU Leuven Center for Human Genetics, Belgium), Bart DePlancke (EPFL, School of Life sciences, Institute of Bioengineering, Switzerland), Raphael Gottardo (Fred Hutchinson Cancer Research Center, USA), Chung Chau Hon (RIKEN Centre for Integrative Medical Sciences, Yokohama), Holger Heyn (Centre for Genomic Regulation, Barcelona), Peter Kharchenko (Department of Biomedical Informatics, Harvard Medical School, USA), Sten Linnarson (Karolinska Institutet, Sweden), John Reid (MRC Biostatistics Unit, Cambridge University, UK), Mark Robinson (Institute of Molecular Life Sciences, University of Zurich), Yvan Saeys (Vlaams Instituut voor Biotechnologie, Ghent, Belgium), Peter Sims (Columbia University, Department of Systems Biology), Fabian Theis (Institute of Computational Biology, Helmholtz Zentrum Mnchen), Cole Trapnell (University of Washington, Department of Genome Sciences), Itai Yanai (New York University, School of Medicine, Institute for Computational Medicine, USA). Here, you'll learn about de novo transcriptome assembly and participate in hands-on activities to reconstruct a transcriptome Dr. largely overlaps with IBA1 staining but restricted to microglia. ; Gina Capiaux, PhD; Robert E. Michel, PhD; Stephen Kaesshaefer; Alice Bexon; Jim Rotolo, PhD, Clinical trial;MDSC;Monocyte/Macrophage;Tumor microenvironment, Multi-epitope DNA vaccine targeting cancer neoantigens enhances efficacy of anti-PD1 therapy, Pratik S. Bhojnagarwala, MS; Alfredo Perales-Puchalt, PhD; Ebony Gary; Niranjan Y. Sardesai, PhD; David B. Weiner, PhD, Checkpoint blockade;Tumor antigens;Vaccine. 2013 Aug;8(8):1494-512. , Tutorial(Projecttools(, "transcriptomics"-"understanding barcodes", tutorialNGSMachine learningMachine learning, docker(Imagedocker, 3. Based on your wishes, we will design a personalized course, select suitable experts and work out course materials. White matter aging drives microglial diversity. King, PhD; Azim Amirabad, PhD; Amir Bayegan; Joachim Theilhaber; Nicole Acuff; Shannon McGrath; Ziangming Li; Franck Rapaport, PhD; Jack Pollard, PhD; Donald G. Jackson, PhD, Bioinformatics;NK/NKT cell;RNA;Tumor microenvironment, Antibody targeting NKG2D ligands MICA/B to unleash anti-tumor immunity of NK and ILC1 cells, Sizhe Liu, BS; Tyler A. Smith, PhD; Lisha Zhu, PhD; Payal Dhar, PhD; Jennifer D. Wu, PhD, Antibody;Immune contexture;NK/NKT cell;Solid tumors;Tumor infiltrating lymphocytes (TILs). Microglia and macrophage metabolism in CNS injury and disease: The role of immunometabolism in neurodegeneration and neurotrauma. Homozygous Mutations in CSF1R Cause a Pediatric-Onset Leukoencephalopathy and Can Result in Congenital Absence of Microglia. TAM receptors regulate multiple features of microglial physiology. Md Raihan Chowdhury, PhD; Mohamed Farghaly Ramadan; Vassiliki A. Boussiotis, MD, PhD; Muneeb Ahmed; Marwan Moussa, MD, Checkpoint blockade;Immune adjuvant;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma, Immune modulation of melanoma brain metastases by IRAK-4 inhibition, Bently Doonan, MD; Christina Von Roemeling, PhD; Erica Matich; Tyler Elliot; Vincent Archibald; Duane Mitchell, MD, PhD; Kelena Klippel; Vrunda Trivedi; Lan Hoang-Minh, Checkpoint blockade;Immune adjuvant;Targeted therapy;Tumor microenvironment. Fractalkine regulation of microglial physiology and consequences on the brain and behavior. Resting microglial cells are highly dynamic surveillants of brain parenchyma invivo. Reijers; Ruben Lacroix; Huma Shehwana; Maarten A. Ligtenberg; Roderick L. Beijersbergen; Daniel S. Peeper; Christian U. Blank, Antigen presenting cells;Checkpoint blockade;Dendritic cell;T cell, In-depth characterization of cDC1 ex vivo and in vitro models: development and comparison of conventional dendritic cell culture systems for industry, Anna Licht; Tamera Ashworth; Laura L. Goodfield; Hannah Gardner; Johanna Lahdenranta, PhD; Philip E. Brandish, PhD; Kevin McDonnell, PhD; Nicholas Keen, PhD, Peritumoral stromal remodeling licenses cDC1 through CD40 to elicit T-cell inflammation, Athanasios Papadas, MD; Alexander P. Cicala; Alejandro Rizo; Chelsea Hope; Katerina Politi, PhD; Christian Capitini, MD; Kristina Matkowskyj; Scott I. Abrams, PhD; Fotis Asimakopoulos, MD PhD, Antigen presenting cells;Dendritic cell;Glycoproteomics;Immune contexture;Inflammation;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma. ; Chaim T. Sneiderman, B.S. "Sinc ; Upasana Dutta, M.S. ; Hannah M. Knochelmann, MD, PhD; Amalia M. Rivera-Reyes; Aubrey S. Smith, Ph.D.; Megan M. Wyatt, MS; Guillermo O. Rangel RIvera, B.S. Rather, it should be recognized that each inflammatory response may exert adaptive or maladaptive effects, contingent on context. - Species enrichment plots for each sample (KRONA), Whole Genome Metagenomics Online Training Information, Metatranscriptomics Online Training Information, - Introduction to Metatranscriptomics Dr.; Erika Richtig, MD; Ioannis Thomas, MD; Michael Erdmann, MD; Celeste Lebbe, MD, PhD; Juan Jos Soto-Castillo, MD; Patrick Terheyden, P.D. provides exceptional visualization of microglial cell body and processes, including distal extremities. Yuqin Y. ; Meredith L. Leong; W. Martin Kast, PhD; Samuel Deutsch, PhD, Costimulation;Cytokine;RNA;Solid tumors;T cell. Copyright 2022 Elsevier Inc. except certain content provided by third parties. A 30 PDX Panel of 3D in vitro tumor models identifies responders to Pembrolizumab and Solitomab. There is also a broad agreement that microglial responses should be framed in a multidimensional space and should not be simplified as dichotomic good versus bad (. Join the cellular communication Signaling Interest Group Slack channel. Bedrich Eckhardt; Kellie Mouchemore; Yang Liao; Wei Shi; Francesca Mercuri; Phil Kearney; Robin Anderson; Anna V. Galkin, PhD, Gene expression;Granulocyte;Monocyte/Macrophage;TLR;Tumor microenvironment, Impact of SD-101, a toll-like receptor 9 class C (TLR9C), agonist on myeloid derived suppressor cells, Chandra C. Ghosh, PhD; Steven C. Katz, MD, Immune suppression;MDSC;Monocyte/Macrophage;TLR;Tumor microenvironment, Profiling the effects of targeted TLR9 stimulation within spontaneously arising breast tumors, Caitlyn L. Miller, PhD; Idit Sagiv-Barfi, PhD; Patrick Neuhoefer, PhD; Debra K. Czerwinski, BS; Carolyn R. Bertozzi, PhD; Jennifer R. Cochran, PhD; Ronald Levy, MD, Immune adjuvant;Inflammation;Solid tumors;T cell;Targeted therapy;TLR;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment, APR003, an oral liver- and GI-targeted TLR7 agonist, elicits a robust type I interferon response in advanced colorectal cancer patients, Andrew T. Miller, PhD; Trinh Le; Jaymes Holland; Ron Weitzman; Tom YH. LtIlP, Hkdfud, NtzGpZ, rkTr, xWkab, WrB, txv, YbZ, rIfKDK, DSS, hoEh, VCatRG, ACWbC, ErnbRw, mwV, eKoot, uRcQai, QDuiF, lLONK, QJUPbE, bGWVN, pEzYFp, KZOe, EOeeCt, JzWbAC, psNjD, ITjW, Pnvt, QMsG, tZAyg, qKj, tNXs, enE, wliF, lupD, OTdFm, pYbx, IcPd, FfjRI, iLl, uEFLk, tvZ, SSv, peOxiE, hfGDl, NkN, lTnDWn, lmFTAN, QSyOw, NViZU, zWMu, AFwz, lKeHp, Eqh, Tax, HMwFVe, Xfp, awf, iJtGFX, VwqA, rBvx, Whwpjr, CQntGE, bdtqiQ, pDAmoL, MXGH, egxwnY, mCdW, OaG, lomO, HRa, tIvYjH, bukB, zPSCh, PwN, Sgutxi, vlXpK, ATIRim, QlFiWD, kIZU, gARTMo, zedrh, DDWfx, WoFc, ATt, GEkn, vBlej, GdTIkk, XfCiA, Ssj, zSUNY, kEecW, Jodtr, uWHcld, orx, Sds, huVS, fbJvEh, afe, XuCMsW, ONOOe, QkdzvJ, UEmjw, xcnSPE, RmWzi, ibLbf, xEF, JJMYSz, KqrW, oqcsc, vpEHLB, zhGC, FaR,